Prokarium is a company that develops a microbial genetics product designed for targeted vaccines and cancer immunotherapies. The company's product generates broad immune responses including mucosal, systemic and cellular immunity for the treatment of solid tumors as well as other oral vaccines, enabling doctors to evaluate the safety and immunogenicity of the bivalent vaccine.